# Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

> **NCT04183790** · PHASE3 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 64 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** ELX/TEZ/IVA
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT04183790
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-17
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-02-24
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04183790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04183790, "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04183790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*